{"protocolSection": {"identificationModule": {"nctId": "NCT02075255", "orgStudyIdInfo": {"id": "D3250C00020"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy", "officialTitle": "A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3 Efficacy and Safety Study of Benralizumab (MEDI-563) to Reduce Oral Corticosteroid Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus Long-acting \u03b22 Agonist and Chronic Oral Corticosteroid Therapy (ZONDA)"}, "statusModule": {"statusVerifiedDate": "2018-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-04-28", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2016-08-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-08-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-02-14", "studyFirstSubmitQcDate": "2014-02-27", "studyFirstPostDateStruct": {"date": "2014-03-03", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-07-24", "resultsFirstSubmitQcDate": "2017-09-15", "resultsFirstPostDateStruct": {"date": "2017-10-17", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-05-10", "lastUpdatePostDateStruct": {"date": "2018-06-08", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this trial is to confirm if benralizumab can reduce the use of maintenance OCS in systemic corticosteroid dependent patients with severe refractory asthma with elevated eosinophils."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive Lung Diseases, OCS, Oral Corticosteroids"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 220, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Benralizumab Arm A", "type": "EXPERIMENTAL", "description": "Benralizumab administered subcutaneously every 4 weeks", "interventionNames": ["Biological: Benralizumab"]}, {"label": "Benralizumab Arm B", "type": "EXPERIMENTAL", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks; matching placebo subcutaneously at the 4 week interim to maintain the blind.", "interventionNames": ["Biological: Benralizumab"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo administered subcutaneously every 4 weeks", "interventionNames": ["Biological: Placebo"]}], "interventions": [{"type": "BIOLOGICAL", "name": "Benralizumab", "description": "Benralizumab administered subcutaneously every 4 weeks", "armGroupLabels": ["Benralizumab Arm A"]}, {"type": "BIOLOGICAL", "name": "Placebo", "description": "Placebo subcutaneously on study week 0 until study week 24 inclusive.", "armGroupLabels": ["Placebo"]}, {"type": "BIOLOGICAL", "name": "Benralizumab", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks; matching placebo subcutaneously at the 4 week interim to maintain the blind.", "armGroupLabels": ["Benralizumab Arm B"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percentage Reduction in Final OCS Dose Compared With Baseline While Maintaining Asthma Control", "description": "Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. The percentage reduction from baseline is defined as: {(Baseline dose-final dose)/baseline dose}\\*100%. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.", "timeFrame": "Week 28"}], "secondaryOutcomes": [{"measure": "Number and Percentage of Patients in Different Categories of Percent Reduction From Baseline in Final OCS Dose While Maintaining Asthma Control", "description": "Number and percentage of patients in different categories of percent reduction from baseline in final OCS dose.", "timeFrame": "Week 28"}, {"measure": "Percentage Reduction in Final OCS Dose Compared With Baseline While Maintaining Asthma Control for Patients With Baseline Eosinophils >=300/uL", "description": "Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. The percentage reduction from baseline is defined as: {(Baseline dose-final dose)/baseline dose}\\*100%. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.", "timeFrame": "Week 28"}, {"measure": "The Percentage of Patients With \u226550% Reduction in Average Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control", "description": "Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. The percentage reduction from baseline is defined as: {(Baseline dose-final dose)/baseline dose}\\*100%. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.", "timeFrame": "Week 28"}, {"measure": "The Proportion of Eligible Patients With \u2265100% Reduction in Average Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control", "description": "Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. The percentage reduction from baseline is defined as: {(Baseline dose-final dose)/baseline dose}\\*100%. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.", "timeFrame": "Week 28"}, {"measure": "The Proportion of Patients With \u22645.0 mg Reduction on Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control.", "description": "Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.", "timeFrame": "Week 28"}, {"measure": "The Proportion of Patients With Average Final OCS Dose \u22645.0 mg Daily at Visit 14, While Maintaining Asthma Control", "description": "Final OCS dose is the dose at Week 28. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.", "timeFrame": "Week 28"}, {"measure": "Number and Percentage of Patients With \u22651 Asthma Exacerbation", "description": "Number and percentage of patients with at least one post randomisation asthma exacerbation.", "timeFrame": "Immediately following the randomisation through Study Week 28"}, {"measure": "Time to the First Asthma Exacerbation", "description": "Time to the first occurrence of asthma exacerbation post randomisation", "timeFrame": "The time from randomisation to the date of first asthma exacerbation over 28 weeks"}, {"measure": "Time to the First Asthma Exacerbation Requiring Hospitalization or ER Visit", "description": "Time to the first exacerbation requiring hospitalization or ER visit post randomisation", "timeFrame": "The time from randomisation to the date of first asthma exacerbation associated with hospitalization or ER over 28 weeks."}, {"measure": "The Annualized Rate of Asthma Exacerbation", "description": "The annualized exacerbation rate is based on unadjudicated exacerbation reported by the investigator adjusted by the time of follow-up.", "timeFrame": "The time from randomisation to the date of week 28 visit (end of treatment) or last contact if the patient is lost to follow up"}, {"measure": "The Annualized Rate of Asthma Exacerbations That Are Associated With an Emergency Room Visit or a Hospitalization", "description": "The annualized exacerbation rate is based on unadjudicated exacerbation reported by the investigator that are associated with an emergency room visit or a hospitalization adjusted by the time of follow-up.", "timeFrame": "The time from randomisation to the date of week 28 visit (end of treatment) or last contact if the patient is lost to follow up"}, {"measure": "Number of Days in Hospital Due to Asthma", "description": "Number of days in hospital due to asthma, if none, 0 day is considered", "timeFrame": "The time from randomisation to the date of week 28 visit (end of treatment) or last contact if the patient is lost to follow up"}, {"measure": "Change From Baseline to Week 28 in Pre-bronchodilator FEV1", "description": "Baseline is defined as the last non-missing value prior to the first dose of study treatment. Change from baseline to Week 28 in two treatment groups is compared to placebo group.", "timeFrame": "Change from baseline at week 28"}, {"measure": "Change From Baseline to Week 28 in Asthma Symptom Scores (Total)", "description": "Asthma symptoms during night time and daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma), and total asthma symptom score is the sum of the daytime and night time score (0 to 6). Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.", "timeFrame": "Change from baseline at week 28"}, {"measure": "Change From Baseline to Week 28 in Asthma Symptom Scores (Daytime)", "description": "Asthma symptoms during daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma). Lower score (0) is indicating better asthma symptom, while higher score (3) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.", "timeFrame": "Change from baseline at week 28"}, {"measure": "Change From Baseline to Week 28 in Asthma Symptom Scores (Nighttime)", "description": "Asthma symptoms during night time are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma). Lower score (0) is indicating better asthma symptom, while higher score (3) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.", "timeFrame": "Change from baseline at week 28"}, {"measure": "Change From Baseline to Week 28 in Rescue Medication Use", "description": "Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this will be considered as missing. The number of inhalations (puffs) per day will be calculated as follows: Number of night inhaler puffs + 2 x \\[number of night nebulizer times\\] + number of day inhaler puffs + 2 x \\[number of day nebulizer times\\].", "timeFrame": "Change from baseline at week 28"}, {"measure": "Change From Baseline to Week 28 in Home Lung Function (Morning Peak Expiratory Flow)", "description": "Morning peak expiratory flow change from baseline to week 28. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data.", "timeFrame": "Change from baseline at week 28"}, {"measure": "Change From Baseline to Week 28 in Home Lung Function (Evening Peak Expiratory Flow)", "description": "Evening peak expiratory flow change from baseline to week 28. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data", "timeFrame": "Change from baseline at week 28"}, {"measure": "Change From Baseline to Week 28 in the Proportion of Nights With Awakening Due to Asthma Requiring Rescue Medication", "description": "Baseline is defined as the proportion of nights from the evening of study day -14 to the morning of study day 1.Each timepoint is calculated as bi-weekly proportions based on daily diary data. If more than 50% of data are missing in a 14 day period then this will be considered as missing.Proportion of nights with noctural awakenings is defined as the number of nights with awakenings due to asthma and requiring rescue medication divided by number of nights with data.", "timeFrame": "Change from baseline at week 28"}, {"measure": "Change From Baseline to Week 28 in ACQ-6", "description": "ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of \\<=0.75 indicates well-controlled asthma, scores between 0.75 to \\<=1.5 indicate partly controlled asthma, and \\>1.5 indicates not well controlled asthma.", "timeFrame": "Change from baseline at week 28"}, {"measure": "ACQ-6 Responders (Improvement) at Week 28", "description": "Improvement is defined as ACQ-6 (End of treatment - baseline) \\<= -0.5. No change is defined as ACQ-6 (End of treatment - baseline) \\>-0.5 and \\<0.5. Deterioration is defined as ACQ-6 (End of treatment - baseline) \\>= 0.5. ACQ-6 score is defined as the average of the first 6 items of the ACQ questionnaire on symptoms, activity limitations and rescue medication.Scores range from 0 (totally controlled) to 6 (severely uncontrolled). Baseline is defined as the last non-missing value prior to randomisation. End of treatment is defined as week 28. Patients with missing or non-evaluable ACQ-6 at week 28 are considered non-responder.", "timeFrame": "Week 28"}, {"measure": "Change From Baseline at Week 28 in AQLQ(S)+12 (Overall)", "description": "AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment). Total or domain score change of \\>=0.5 are considered clinically meaningful.", "timeFrame": "Change from baseline at week 28"}, {"measure": "AQLQ(s)+12 Responders (Improvement) at Week 28", "description": "AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. Improvement is defined as AQLQ(S)+12 (End of treatment - baseline)\\>=0.5. No change is defined as AQLQ(S)+12 (End of treatment - baseline) \\>-0.5 and \\<0.5. Deterioration is defined as AQLQ(S)+12 (End of treatment - baseline) \\<= -0.5. Baseline is defined as the last AQLQ(S)+12 score prior to randomisation. End of treatment is defined as week 28. Patients with missing or non-evaluable score at week 28 are considered as non-responder.", "timeFrame": "Week 28"}, {"measure": "Extent of Exposure", "description": "Duration of exposure from first dose date to last dose date.", "timeFrame": "From first dose to Week 24"}, {"measure": "Serum Concentration of Benralizumab", "description": "Pre-dose serum concentrations at each visit", "timeFrame": "Pre-first dose to Week 36"}, {"measure": "Anti-drug Antibody Response", "description": "Number and percentage of patients in different ADA response categories", "timeFrame": "From baseline to follow-up Week 36"}, {"measure": "Percent Change From Baseline in Blood Eosinophil Counts", "description": "Percent change from baseline in blood eosinophil counts at week 28", "timeFrame": "Change from baseline at Week 28"}, {"measure": "Total Lung Capacity", "description": "Change from baseline in total lung capacity", "timeFrame": "From baseline to Week 28"}, {"measure": "Residual Volume", "description": "Change from baseline in residual volume", "timeFrame": "From baseline to Week 28"}, {"measure": "Vital Capacity", "description": "Change from baseline in vital capacity", "timeFrame": "From baseline to Week 28"}, {"measure": "Functional Residual Capacity", "description": "Change from baseline in functional residual capacity", "timeFrame": "From baseline to Week 28"}, {"measure": "Inspiratory Capacity", "description": "Change from baseline in inspiratory capacity", "timeFrame": "From baseline to Week 28"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Provision of informed consent prior to any study specific procedures.\n2. Female and male aged from 18 to 75 years, inclusively.\n3. History of physician-diagnosed asthma requiring treatment with medium dose ICS and LABA.\n4. Elevated level of peripheral blood eosinophil\n5. Documented treatment with high-dose ICS and LABA for at least 6 months prior to Visit 1\n6. Chronic oral corticosteroid therapy for at least 6 continuous months directly preceding Visit 1. Subjects must be on doses equivalent to 7.5 - 40 mg/day of prednisolone/prednisone at Visit 1 and be on a stable dose for at least 2 weeks prior to randomization. Patients must agree to switch to study required prednisone/prednisolone as their oral corticosteroid for the duration of the study.\n7. Patients with documented failures of OCS reduction within 6 months prior to Visit 1 will not be required to proceed through the dose optimization phase during run-in.\n8. Morning pre-bronchodilator (Pre-BD) FEV1 of \\<80% predicted\n9. Evidence of asthma as documented by either:\n\n   Airway reversibility (FEV1 \u226512% and 200 mL) demonstrated at Visit 1, Visit 2, or Visit 3 using the Maximum Post-bronchodilator Procedure OR Documented reversibility in the previous 24 months prior to Visit 1 OR Airway hyperresponsiveness (PC20 FEV1 methacholine concentration \u22648mg/mL) documented in the previous 12 months prior to planned date of randomization OR Airflow variability in clinic FEV1 \u226520% between 2 consecutive clinic visits documented in the 12 months prior to the planned date of randomization (FEV1 recorded during an exacerbation should not be considered for this criterion).\n\n   All patients must have reversibility testing performed before randomization to establish a baseline characteristic.\n\n   If patients do not demonstrate airway reversibility at either Visit 1 or Visit 2 and this is needed to qualify the patient for randomization, the site should reiterate the need to withhold short- and long-acting bronchodilators prior to Visit 3 in an effort to meet this inclusion criterion.\n10. At least 1 documented asthma exacerbation in the previous 12 months prior to the date informed consent is obtained\n11. Optimized OCS dose reached at least 2 weeks prior to randomization\n12. Additional asthma controller medication must not have been initiated during run in/optimization period (not applicable for management of exacerbations during screening/ run in optimization phase)\n13. At least 70% compliance with OCS use\n14. At least 70% compliance with usual asthma controller ICS-LABA\n15. Minimum 70% (i.e. 10 of 14 days) compliance with asthma daily diary (morning and evening diary)\n\nExclusion criteria:\n\n1. Clinically important pulmonary disease other than asthma or ever been diagnosed with pulmonary or systemic disease, other than asthma, that are associated with elevated peripheral eosinophil counts.\n2. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could:\n\n   * Affect the safety of the patient throughout the study\n   * Influence the findings of the studies or their interpretations\n   * Impede the patient's ability to complete the entire duration of study\n3. Acute upper or lower respiratory infections requiring antibiotics or antiviral medication within 30 days prior to the date informed consent is obtained or during the screening/run-in period\n4. Any clinically significant abnormal findings in physical examination, vital signs, hematology, clinical chemistry, or urinalysis during run-in/optimization period, which in the opinion of the Investigator, may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or the patient's ability to complete entire duration of the study\n5. History of life-threatening asthma\n6. Asthma control reached at an OCS dose of \u22645mg during run-in/OCS optimization phase\n7. Qualifies for 3 consecutive dose reductions at Visits 2-4 and continues to meet OCS dose reduction criteria at Visit 5\n8. Receipt of oral corticosteroids, other than prednisone or prednisolone, as the maintenance oral steroid controller for asthma symptoms from Visit 1 and throughout the study.\n9. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level \u22652.5 times the upper limit of normal (ULN) confirmed during screening period", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Parameswaran Nair, MD,PhD,FRCP,FRCPC", "affiliation": "St Joseph's Healthcare Hamilton Firestone Institute for Respiratory Health 50 Charlton Avenue East Hamilton", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Research Site", "city": "Los Angeles", "state": "California", "zip": "90025", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Research Site", "city": "Centennial", "state": "Colorado", "zip": "80112", "country": "United States", "geoPoint": {"lat": 39.57916, "lon": -104.87692}}, {"facility": "Research Site", "city": "Denver", "state": "Colorado", "zip": "80206", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Research Site", "city": "Hialeah", "state": "Florida", "zip": "33010", "country": "United States", "geoPoint": {"lat": 25.8576, "lon": -80.27811}}, {"facility": "Research Site", "city": "Hialeah", "state": "Florida", "zip": "33013", "country": "United States", "geoPoint": {"lat": 25.8576, "lon": -80.27811}}, {"facility": "Research Site", "city": "Miami", "state": "Florida", "zip": "33015", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Research Site", "city": "Orlando", "state": "Florida", "zip": "32825", "country": "United States", "geoPoint": {"lat": 28.53834, "lon": -81.37924}}, {"facility": "Research Site", "city": "Iowa City", "state": "Iowa", "zip": "52242", "country": "United States", "geoPoint": {"lat": 41.66113, "lon": -91.53017}}, {"facility": "Research Site", "city": "Fort Mitchell", "state": "Kentucky", "zip": "41017", "country": "United States", "geoPoint": {"lat": 39.0595, "lon": -84.54744}}, {"facility": "Research Site", "city": "Rochester", "state": "Minnesota", "zip": "55905", "country": "United States", "geoPoint": {"lat": 44.02163, "lon": -92.4699}}, {"facility": "Research Site", "city": "Bronx", "state": "New York", "zip": "10461", "country": "United States", "geoPoint": {"lat": 40.84985, "lon": -73.86641}}, {"facility": "Research Site", "city": "Durham", "state": "North Carolina", "zip": "27704", "country": "United States", "geoPoint": {"lat": 35.99403, "lon": -78.89862}}, {"facility": "Research Site", "city": "Winston-Salem", "state": "North Carolina", "zip": "27103", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "Research Site", "city": "Cincinnati", "state": "Ohio", "zip": "45231", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Research Site", "city": "Middleburg Heights", "state": "Ohio", "zip": "44130", "country": "United States", "geoPoint": {"lat": 41.36144, "lon": -81.81291}}, {"facility": "Research Site", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73112", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Research Site", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19140", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Research Site", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15213", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Research Site", "city": "Mount Pleasant", "state": "South Carolina", "zip": "29464", "country": "United States", "geoPoint": {"lat": 32.79407, "lon": -79.86259}}, {"facility": "Research Site", "city": "Madison", "state": "Wisconsin", "zip": "53792", "country": "United States", "geoPoint": {"lat": 43.07305, "lon": -89.40123}}, {"facility": "Research Site", "city": "Buenos Aires", "zip": "C1414AIF", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Research Site", "city": "Caba", "zip": "1426", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Research Site", "city": "Florida", "zip": "1638", "country": "Argentina"}, {"facility": "Research Site", "city": "Mendoza", "zip": "5500", "country": "Argentina", "geoPoint": {"lat": -32.89084, "lon": -68.82717}}, {"facility": "Research Site", "city": "Kozloduy", "zip": "3320", "country": "Bulgaria", "geoPoint": {"lat": 43.77867, "lon": 23.72067}}, {"facility": "Research Site", "city": "Pazardzhik", "zip": "4400", "country": "Bulgaria", "geoPoint": {"lat": 42.2, "lon": 24.33333}}, {"facility": "Research Site", "city": "Petrich", "zip": "2850", "country": "Bulgaria", "geoPoint": {"lat": 41.39847, "lon": 23.20705}}, {"facility": "Research Site", "city": "Ruse", "zip": "7002", "country": "Bulgaria", "geoPoint": {"lat": 43.85639, "lon": 25.97083}}, {"facility": "Research Site", "city": "Samokov", "zip": "2000", "country": "Bulgaria", "geoPoint": {"lat": 42.337, "lon": 23.5528}}, {"facility": "Research Site", "city": "Vratsa", "zip": "3000", "country": "Bulgaria", "geoPoint": {"lat": 43.21, "lon": 23.5625}}, {"facility": "Research Site", "city": "Calgary", "state": "Alberta", "zip": "T2N 4Z6", "country": "Canada", "geoPoint": {"lat": 51.05011, "lon": -114.08529}}, {"facility": "Research Site", "city": "Vancouver", "state": "British Columbia", "zip": "V6Z 1Y6", "country": "Canada", "geoPoint": {"lat": 49.24966, "lon": -123.11934}}, {"facility": "Research Site", "city": "Hamilton", "state": "Ontario", "zip": "L8N 4A6", "country": "Canada", "geoPoint": {"lat": 43.25011, "lon": -79.84963}}, {"facility": "Research Site", "city": "Ottawa", "state": "Ontario", "zip": "K1G 6C6", "country": "Canada", "geoPoint": {"lat": 45.41117, "lon": -75.69812}}, {"facility": "Research Site", "city": "Montreal", "state": "Quebec", "zip": "H4A 3J1", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Research Site", "city": "Quebec", "zip": "G1V 4G5", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "Research Site", "city": "Quillota", "country": "Chile", "geoPoint": {"lat": -32.88341, "lon": -71.24882}}, {"facility": "Research Site", "city": "Rancagua", "zip": "2820000", "country": "Chile", "geoPoint": {"lat": -34.17083, "lon": -70.74444}}, {"facility": "Research Site", "city": "Santiago", "zip": "8380453", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "Research Site", "city": "Talcahuano", "zip": "4270918", "country": "Chile", "geoPoint": {"lat": -36.72494, "lon": -73.11684}}, {"facility": "Research Site", "city": "Talca", "zip": "3465584", "country": "Chile", "geoPoint": {"lat": -35.4264, "lon": -71.65542}}, {"facility": "Research Site", "city": "Valparaiso", "zip": "2341131", "country": "Chile", "geoPoint": {"lat": -33.03932, "lon": -71.62725}}, {"facility": "Research Site", "city": "Brest Cedex 2", "zip": "29609", "country": "France", "geoPoint": {"lat": 48.3903, "lon": -4.48628}}, {"facility": "Research Site", "city": "Lyon Cedex 04", "zip": "69317", "country": "France", "geoPoint": {"lat": 45.74848, "lon": 4.84669}}, {"facility": "Research Site", "city": "Marseille", "zip": "13015", "country": "France", "geoPoint": {"lat": 43.29551, "lon": 5.38958}}, {"facility": "Research Site", "city": "Montpellier", "zip": "34295", "country": "France", "geoPoint": {"lat": 43.61092, "lon": 3.87723}}, {"facility": "Research Site", "city": "Strasbourg Cedex", "zip": "67091", "country": "France", "geoPoint": {"lat": 48.58392, "lon": 7.74553}}, {"facility": "Research Site", "city": "Toulouse", "zip": "31059", "country": "France", "geoPoint": {"lat": 43.60426, "lon": 1.44367}}, {"facility": "Research Site", "city": "Bamberg", "zip": "96049", "country": "Germany", "geoPoint": {"lat": 49.89873, "lon": 10.90067}}, {"facility": "Research Site", "city": "Berlin", "zip": "10119", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Research Site", "city": "Freiburg", "zip": "79106", "country": "Germany", "geoPoint": {"lat": 47.9959, "lon": 7.85222}}, {"facility": "Research Site", "city": "Grosshansdorf", "zip": "20927", "country": "Germany", "geoPoint": {"lat": 53.66667, "lon": 10.28333}}, {"facility": "Research Site", "city": "Hannover", "zip": "30625", "country": "Germany", "geoPoint": {"lat": 52.37052, "lon": 9.73322}}, {"facility": "Research Site", "city": "Leipzig", "zip": "04207", "country": "Germany", "geoPoint": {"lat": 51.33962, "lon": 12.37129}}, {"facility": "Research Site", "city": "Mainz", "zip": "55131", "country": "Germany", "geoPoint": {"lat": 49.98419, "lon": 8.2791}}, {"facility": "Research Site", "city": "Seoul", "zip": "02559", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Seoul", "zip": "03080", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Seoul", "zip": "03722", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Seoul", "zip": "06591", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Seoul", "zip": "135-710", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Suwon-si", "zip": "16499", "country": "Korea, Republic of", "geoPoint": {"lat": 37.29111, "lon": 127.00889}}, {"facility": "Research Site", "city": "Bydgoszcz", "zip": "85-231", "country": "Poland", "geoPoint": {"lat": 53.1235, "lon": 18.00762}}, {"facility": "Research Site", "city": "Karczew", "zip": "05-480", "country": "Poland", "geoPoint": {"lat": 52.07655, "lon": 21.24962}}, {"facility": "Research Site", "city": "Koszalin", "zip": "75-679", "country": "Poland", "geoPoint": {"lat": 54.19438, "lon": 16.17222}}, {"facility": "Research Site", "city": "Krak\u00f3w", "zip": "31-011", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Research Site", "city": "Krak\u00f3w", "zip": "31-159", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Research Site", "city": "Lubin", "zip": "59-300", "country": "Poland", "geoPoint": {"lat": 51.40089, "lon": 16.20149}}, {"facility": "Research Site", "city": "Szczecin", "zip": "70-111", "country": "Poland", "geoPoint": {"lat": 53.42894, "lon": 14.55302}}, {"facility": "Research Site", "city": "Tarn\u00f3w", "zip": "33-100", "country": "Poland", "geoPoint": {"lat": 50.01381, "lon": 20.98698}}, {"facility": "Research Site", "city": "Trzebnica", "zip": "55-100", "country": "Poland", "geoPoint": {"lat": 51.31076, "lon": 17.06331}}, {"facility": "Research Site", "city": "Wroclaw", "zip": "53-201", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "Research Site", "city": "Wroc\u0142aw", "zip": "53-301", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "Research Site", "city": "\u0141\u00f3d\u017a", "zip": "90-141", "country": "Poland", "geoPoint": {"lat": 51.75, "lon": 19.46667}}, {"facility": "Research Site", "city": "M\u00e1laga", "zip": "29010", "country": "Spain", "geoPoint": {"lat": 36.72016, "lon": -4.42034}}, {"facility": "Research Site", "city": "Valencia", "zip": "46017", "country": "Spain", "geoPoint": {"lat": 39.46975, "lon": -0.37739}}, {"facility": "Research Site", "city": "Adana", "zip": "01330", "country": "Turkey", "geoPoint": {"lat": 37.00167, "lon": 35.32889}}, {"facility": "Research Site", "city": "Ankara", "zip": "06230", "country": "Turkey", "geoPoint": {"lat": 39.91987, "lon": 32.85427}}, {"facility": "Research Site", "city": "Bursa", "country": "Turkey", "geoPoint": {"lat": 40.19559, "lon": 29.06013}}, {"facility": "Research Site", "city": "Istanbul", "zip": "34098", "country": "Turkey", "geoPoint": {"lat": 41.01384, "lon": 28.94966}}, {"facility": "Research Site", "city": "\u0130stanbul", "zip": "34844", "country": "Turkey", "geoPoint": {"lat": 41.01384, "lon": 28.94966}}, {"facility": "Research Site", "city": "Dnipropetrovsk", "zip": "49007", "country": "Ukraine", "geoPoint": {"lat": 48.4593, "lon": 35.03864}}, {"facility": "Research Site", "city": "Ivano-Frankivsk", "zip": "76012", "country": "Ukraine", "geoPoint": {"lat": 48.9215, "lon": 24.70972}}, {"facility": "Research Site", "city": "Kharkiv", "zip": "61035", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"facility": "Research Site", "city": "Kharkiv", "zip": "61039", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"facility": "Research Site", "city": "Kyiv", "zip": "03680", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Research Site", "city": "Kyiv", "zip": "04201", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Research Site", "city": "Vinnytsia", "zip": "21029", "country": "Ukraine", "geoPoint": {"lat": 49.23278, "lon": 28.48097}}]}, "referencesModule": {"references": [{"pmid": "28530840", "type": "BACKGROUND", "citation": "Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, Barker P, Sproule S, Ponnarambil S, Goldman M; ZONDA Trial Investigators. Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. N Engl J Med. 2017 Jun 22;376(25):2448-2458. doi: 10.1056/NEJMoa1703501. Epub 2017 May 22."}, {"pmid": "35287231", "type": "DERIVED", "citation": "Menzies-Gow A, Hoyte FL, Price DB, Cohen D, Barker P, Kreindler J, Jison M, Brooks CL, Papeleu P, Katial R. Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab. Adv Ther. 2022 May;39(5):2065-2084. doi: 10.1007/s12325-022-02098-1. Epub 2022 Mar 14."}, {"pmid": "31579676", "type": "DERIVED", "citation": "Menzies-Gow A, Corren J, Bel EH, Maspero J, Heaney LG, Gurnell M, Wessman P, Martin UJ, Siddiqui S, Garcia Gil E. Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial. ERJ Open Res. 2019 Sep 25;5(3):00009-2019. doi: 10.1183/23120541.00009-2019. eCollection 2019 Jul."}, {"pmid": "30802500", "type": "DERIVED", "citation": "Chupp G, Lugogo NL, Kline JN, Ferguson GT, Hirsch I, Goldman M, Zangrilli JG, Trudo F. Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthma. Ann Allergy Asthma Immunol. 2019 May;122(5):478-485. doi: 10.1016/j.anai.2019.02.016. Epub 2019 Feb 23."}], "seeAlsoLinks": [{"label": "CSP redacted", "url": "http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=2559&filename=Nair_ZONDA_CSP_REDACTED.pdf"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "369 participants signed informed consent. 271 entered run in/OCS optimization period. 220 participants were randomized to receive treatment with benralizumab 30 mg Q4W, Q8W, or placebo. Of the 220 patients randomised, all (100.0%) received treatment with study drug", "groups": [{"id": "FG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "FG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks"}, {"id": "FG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "72"}, {"groupId": "FG001", "numSubjects": "73"}, {"groupId": "FG002", "numSubjects": "75"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "68"}, {"groupId": "FG001", "numSubjects": "69"}, {"groupId": "FG002", "numSubjects": "72"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Study specific withdrawal criteria", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "BG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks"}, {"id": "BG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "72"}, {"groupId": "BG001", "value": "73"}, {"groupId": "BG002", "value": "75"}, {"groupId": "BG003", "value": "220"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "50.2", "spread": "12.0"}, {"groupId": "BG001", "value": "52.9", "spread": "10.1"}, {"groupId": "BG002", "value": "49.9", "spread": "11.7"}, {"groupId": "BG003", "value": "51.0", "spread": "11.3"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "40"}, {"groupId": "BG001", "value": "47"}, {"groupId": "BG002", "value": "48"}, {"groupId": "BG003", "value": "135"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "32"}, {"groupId": "BG001", "value": "26"}, {"groupId": "BG002", "value": "27"}, {"groupId": "BG003", "value": "85"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percentage Reduction in Final OCS Dose Compared With Baseline While Maintaining Asthma Control", "description": "Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. The percentage reduction from baseline is defined as: {(Baseline dose-final dose)/baseline dose}\\*100%. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.", "populationDescription": "Full analysis set", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent", "timeFrame": "Week 28", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "72"}, {"groupId": "OG001", "value": "73"}, {"groupId": "OG002", "value": "75"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "75.00", "lowerLimit": "50.00", "upperLimit": "83.30"}, {"groupId": "OG001", "value": "75.00", "lowerLimit": "60.00", "upperLimit": "87.50"}, {"groupId": "OG002", "value": "25.00", "lowerLimit": "0.00", "upperLimit": "33.30"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Wilcoxon (Mann-Whitney)", "paramType": "Median Difference (Final Values)", "paramValue": "33.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "16.70", "ciUpperLimit": "50.00", "estimateComment": "Hodges-Lehmann estimate is used."}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Wilcoxon (Mann-Whitney)", "paramType": "Median Difference (Final Values)", "paramValue": "37.50", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "20.80", "ciUpperLimit": "50.00", "estimateComment": "Hodges Lehmann estimate is used."}]}, {"type": "SECONDARY", "title": "Number and Percentage of Patients in Different Categories of Percent Reduction From Baseline in Final OCS Dose While Maintaining Asthma Control", "description": "Number and percentage of patients in different categories of percent reduction from baseline in final OCS dose.", "populationDescription": "Full analysis set", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Week 28", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "72"}, {"groupId": "OG001", "value": "73"}, {"groupId": "OG002", "value": "75"}]}], "classes": [{"title": ">=90% reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "27"}, {"groupId": "OG002", "value": "9"}]}]}, {"title": ">=75% reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "38"}, {"groupId": "OG001", "value": "37"}, {"groupId": "OG002", "value": "15"}]}]}, {"title": ">=50% reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "48"}, {"groupId": "OG002", "value": "28"}]}]}, {"title": ">0% reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "55"}, {"groupId": "OG001", "value": "58"}, {"groupId": "OG002", "value": "40"}]}]}, {"title": "No change or any increase", "categories": [{"measurements": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "15"}, {"groupId": "OG002", "value": "35"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "proportional odds model", "statisticalComment": "Controlling for treatment group, region, and baseline OCS dose.", "paramType": "Odds Ratio (OR)", "paramValue": "4.09", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.22", "ciUpperLimit": "7.57"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "proportional odds model", "statisticalComment": "Controlling for treatment group, region, and baseline OCS dose.", "paramType": "Odds Ratio (OR)", "paramValue": "4.12", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.22", "ciUpperLimit": "7.63"}]}, {"type": "SECONDARY", "title": "Percentage Reduction in Final OCS Dose Compared With Baseline While Maintaining Asthma Control for Patients With Baseline Eosinophils >=300/uL", "description": "Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. The percentage reduction from baseline is defined as: {(Baseline dose-final dose)/baseline dose}\\*100%. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.", "populationDescription": "Full analysis set, baseline blood eosinophil \\>=300/uL", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent", "timeFrame": "Week 28", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "61"}, {"groupId": "OG002", "value": "64"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "75.00", "lowerLimit": "60.00", "upperLimit": "100.00"}, {"groupId": "OG001", "value": "75.00", "lowerLimit": "60.00", "upperLimit": "91.70"}, {"groupId": "OG002", "value": "0.00", "lowerLimit": "0.00", "upperLimit": "28.60"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Wilcoxon (Mann-Whitney)", "paramType": "Median Difference (Final Values)", "paramValue": "50.00", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "25.00", "ciUpperLimit": "66.70", "estimateComment": "Hodges Lehmann estimate is used."}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Wilcoxon (Mann-Whitney)", "paramType": "Median Difference (Final Values)", "paramValue": "50.00", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "25.00", "ciUpperLimit": "66.70", "estimateComment": "Hodges Lehmann estimate is used."}]}, {"type": "SECONDARY", "title": "The Percentage of Patients With \u226550% Reduction in Average Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control", "description": "Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. The percentage reduction from baseline is defined as: {(Baseline dose-final dose)/baseline dose}\\*100%. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.", "populationDescription": "Full analysis set", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Week 28", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "72"}, {"groupId": "OG001", "value": "73"}, {"groupId": "OG002", "value": "75"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "48"}, {"groupId": "OG002", "value": "28"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Cochran-Mantel-Haenszel", "statisticalComment": "Controlling for region.", "paramType": "Odds Ratio (OR)", "paramValue": "3.59", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.79", "ciUpperLimit": "7.22"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Cochran-Mantel-Haenszel", "statisticalComment": "Controlling for region.", "paramType": "Odds Ratio (OR)", "paramValue": "3.03", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.57", "ciUpperLimit": "5.86"}]}, {"type": "SECONDARY", "title": "The Proportion of Eligible Patients With \u2265100% Reduction in Average Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control", "description": "Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. The percentage reduction from baseline is defined as: {(Baseline dose-final dose)/baseline dose}\\*100%. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.", "populationDescription": "Full analysis set, eligible for 100% reduction (ie, patients with baseline OCS dose \\<= 12.5 mg)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Week 28", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "42"}, {"groupId": "OG002", "value": "42"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Cochran-Mantel-Haenszel", "statisticalComment": "Controlling for region.", "paramType": "Odds Ratio (OR)", "paramValue": "5.23", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.92", "ciUpperLimit": "14.21"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.002", "statisticalMethod": "Cochran-Mantel-Haenszel", "statisticalComment": "Controlling for region.", "paramType": "Odds Ratio (OR)", "paramValue": "4.19", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.58", "ciUpperLimit": "11.12"}]}, {"type": "SECONDARY", "title": "The Proportion of Patients With \u22645.0 mg Reduction on Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control.", "description": "Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.", "populationDescription": "Full analysis set", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Week 28", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "72"}, {"groupId": "OG001", "value": "73"}, {"groupId": "OG002", "value": "75"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "25"}, {"groupId": "OG002", "value": "38"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.012", "statisticalMethod": "Cochran-Mantel-Haenszel", "statisticalComment": "Controlling for region.", "paramType": "Odds Ratio (OR)", "paramValue": "0.42", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.21", "ciUpperLimit": "0.83"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.053", "statisticalMethod": "Cochran-Mantel-Haenszel", "statisticalComment": "Controlling for region.", "paramType": "Odds Ratio (OR)", "paramValue": "0.52", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.27", "ciUpperLimit": "1.01"}]}, {"type": "SECONDARY", "title": "The Proportion of Patients With Average Final OCS Dose \u22645.0 mg Daily at Visit 14, While Maintaining Asthma Control", "description": "Final OCS dose is the dose at Week 28. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.", "populationDescription": "Full analysis set", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Week 28", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "72"}, {"groupId": "OG001", "value": "73"}, {"groupId": "OG002", "value": "75"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "44"}, {"groupId": "OG001", "value": "43"}, {"groupId": "OG002", "value": "25"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Cochran-Mantel-Haenszel", "statisticalComment": "Controlling for region.", "paramType": "Odds Ratio (OR)", "paramValue": "3.16", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.60", "ciUpperLimit": "6.23"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.002", "statisticalMethod": "Cochran-Mantel-Haenszel", "statisticalComment": "Controlling for region.", "paramType": "Odds Ratio (OR)", "paramValue": "2.74", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.41", "ciUpperLimit": "5.31"}]}, {"type": "SECONDARY", "title": "Number and Percentage of Patients With \u22651 Asthma Exacerbation", "description": "Number and percentage of patients with at least one post randomisation asthma exacerbation.", "populationDescription": "Full analysis set", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Immediately following the randomisation through Study Week 28", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "72"}, {"groupId": "OG001", "value": "73"}, {"groupId": "OG002", "value": "75"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "39"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.001", "statisticalMethod": "Cochran-Mantel-Haenszel", "statisticalComment": "Controlling for region.", "paramType": "Odds Ratio (OR)", "paramValue": "0.32", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.16", "ciUpperLimit": "0.65"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Cochran-Mantel-Haenszel", "statisticalComment": "Controlling for region.", "paramType": "Odds Ratio (OR)", "paramValue": "0.28", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.14", "ciUpperLimit": "0.56"}]}, {"type": "SECONDARY", "title": "Time to the First Asthma Exacerbation", "description": "Time to the first occurrence of asthma exacerbation post randomisation", "populationDescription": "Full analysis set", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Days", "timeFrame": "The time from randomisation to the date of first asthma exacerbation over 28 weeks", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "72"}, {"groupId": "OG001", "value": "73"}, {"groupId": "OG002", "value": "75"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "median survival time is not estimable due to number of exacerbations had not reached 50%."}, {"groupId": "OG001", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "median survival time is not estimable due to number of exacerbations had not reached 50%."}, {"groupId": "OG002", "value": "155", "lowerLimit": "111", "upperLimit": "NA", "comment": "Upper 95% CI for median is not estimable due to the curve representing the upper confidence limit of the survival function is above 50%"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Regression, Cox", "statisticalComment": "Including covariates treatment group, region, number of exacerbations in the previous year.", "paramType": "Hazard Ratio (HR)", "paramValue": "0.39", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.22", "ciUpperLimit": "0.66"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Regression, Cox", "statisticalComment": "Including covariates treatment group, region, number of exacerbations in the previous year.", "paramType": "Hazard Ratio (HR)", "paramValue": "0.32", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.17", "ciUpperLimit": "0.57"}]}, {"type": "SECONDARY", "title": "Time to the First Asthma Exacerbation Requiring Hospitalization or ER Visit", "description": "Time to the first exacerbation requiring hospitalization or ER visit post randomisation", "populationDescription": "Full analysis set", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Days", "timeFrame": "The time from randomisation to the date of first asthma exacerbation associated with hospitalization or ER over 28 weeks.", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "72"}, {"groupId": "OG001", "value": "73"}, {"groupId": "OG002", "value": "75"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "median survival time is not estimable due to number of exacerbations resulting hospitalization or ER visit had not reached 50%."}, {"groupId": "OG001", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "median survival time is not estimable due to number of exacerbations resulting hospitalization or ER visit had not reached 50%."}, {"groupId": "OG002", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "median survival time is not estimable due to number of exacerbations resulting hospitalization or ER visit had not reached 50%."}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.291", "statisticalMethod": "Regression, Cox", "statisticalComment": "Including covariates treatment group, region, any exacerbations in the previous year requiring hospitalization or ER visit.", "paramType": "Hazard Ratio (HR)", "paramValue": "0.53", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.14", "ciUpperLimit": "1.64"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.042", "statisticalMethod": "Regression, Cox", "statisticalComment": "Including covariates treatment group, region, any exacerbations in the previous year requiring hospitalization or ER visit.", "paramType": "Hazard Ratio (HR)", "paramValue": "0.12", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.01", "ciUpperLimit": "0.63"}]}, {"type": "SECONDARY", "title": "The Annualized Rate of Asthma Exacerbation", "description": "The annualized exacerbation rate is based on unadjudicated exacerbation reported by the investigator adjusted by the time of follow-up.", "populationDescription": "Full analysis set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "events/year", "timeFrame": "The time from randomisation to the date of week 28 visit (end of treatment) or last contact if the patient is lost to follow up", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "72"}, {"groupId": "OG001", "value": "73"}, {"groupId": "OG002", "value": "75"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.83", "lowerLimit": "0.55", "upperLimit": "1.26"}, {"groupId": "OG001", "value": "0.54", "lowerLimit": "0.34", "upperLimit": "0.88"}, {"groupId": "OG002", "value": "1.83", "lowerLimit": "1.33", "upperLimit": "2.50"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.003", "statisticalMethod": "negative binomial model", "statisticalComment": "Including covariates treatment group, region, number of exacerbations in the previous year. The log of follow-up time is used as offset variable.", "paramType": "Rate ratio", "paramValue": "0.45", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.27", "ciUpperLimit": "0.76"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "negative binomial model", "statisticalComment": "Including covariates treatment group, region, number of exacerbations in the previous year. The log of follow-up time is used as offset variable.", "paramType": "Rate ratio", "paramValue": "0.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.17", "ciUpperLimit": "0.53"}]}, {"type": "SECONDARY", "title": "The Annualized Rate of Asthma Exacerbations That Are Associated With an Emergency Room Visit or a Hospitalization", "description": "The annualized exacerbation rate is based on unadjudicated exacerbation reported by the investigator that are associated with an emergency room visit or a hospitalization adjusted by the time of follow-up.", "populationDescription": "Full analysis set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "events/year", "timeFrame": "The time from randomisation to the date of week 28 visit (end of treatment) or last contact if the patient is lost to follow up", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "72"}, {"groupId": "OG001", "value": "73"}, {"groupId": "OG002", "value": "75"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.14", "lowerLimit": "0.05", "upperLimit": "0.38"}, {"groupId": "OG001", "value": "0.02", "lowerLimit": "0.00", "upperLimit": "0.18"}, {"groupId": "OG002", "value": "0.32", "lowerLimit": "0.16", "upperLimit": "0.65"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.187", "statisticalMethod": "negative binomial model", "statisticalComment": "Covariates include treatment, region, any exacerbations in the previous year requiring hospitalization/ER. Log of follow-up time is the offset.", "paramType": "Rate ratio", "paramValue": "0.44", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.13", "ciUpperLimit": "1.49"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.018", "statisticalMethod": "negative binomial model", "statisticalComment": "Covariates include treatment, region, any exacerbations in the previous year requiring hospitalization/ER. Log of follow-up time is the offset.", "paramType": "Rate ratio", "paramValue": "0.07", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.01", "ciUpperLimit": "0.63"}]}, {"type": "SECONDARY", "title": "Number of Days in Hospital Due to Asthma", "description": "Number of days in hospital due to asthma, if none, 0 day is considered", "populationDescription": "Full analysis set", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Days", "timeFrame": "The time from randomisation to the date of week 28 visit (end of treatment) or last contact if the patient is lost to follow up", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "72"}, {"groupId": "OG001", "value": "73"}, {"groupId": "OG002", "value": "75"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.3", "spread": "1.41", "lowerLimit": "0.02", "upperLimit": "0.19"}, {"groupId": "OG001", "value": "0.5", "spread": "3.86", "lowerLimit": "0.00", "upperLimit": "0.08"}, {"groupId": "OG002", "value": "1.2", "spread": "6.66", "lowerLimit": "0.04", "upperLimit": "0.35"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 28 in Pre-bronchodilator FEV1", "description": "Baseline is defined as the last non-missing value prior to the first dose of study treatment. Change from baseline to Week 28 in two treatment groups is compared to placebo group.", "populationDescription": "Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liter", "timeFrame": "Change from baseline at week 28", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "68"}, {"groupId": "OG001", "value": "68"}, {"groupId": "OG002", "value": "73"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.230", "spread": "0.429"}, {"groupId": "OG001", "value": "0.255", "spread": "0.508"}, {"groupId": "OG002", "value": "0.114", "spread": "0.401"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.153", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Including covariates: treatment group, region, baseline pre-BD FEV1 value, visit, and visit by treatment interaction.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.105", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.040", "ciUpperLimit": "0.251"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.129", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Including covariates: treatment group, region, baseline pre-BD FEV1 value, visit, and visit by treatment interaction.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.112", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.033", "ciUpperLimit": "0.258"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 28 in Asthma Symptom Scores (Total)", "description": "Asthma symptoms during night time and daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma), and total asthma symptom score is the sum of the daytime and night time score (0 to 6). Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.", "populationDescription": "Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Change from baseline at week 28", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "67"}, {"groupId": "OG001", "value": "68"}, {"groupId": "OG002", "value": "67"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.58", "spread": "1.03"}, {"groupId": "OG001", "value": "-0.77", "spread": "1.03"}, {"groupId": "OG002", "value": "-0.58", "spread": "1.03"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.947", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Include covariates: treatment group, baseline asthma symptom score, region, visit, and treatment by visit interaction.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.01", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.35", "ciUpperLimit": "0.32"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.291", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Include covariates: treatment group, baseline asthma symptom score, region, visit, and treatment by visit interaction.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.18", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.51", "ciUpperLimit": "0.16"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 28 in Asthma Symptom Scores (Daytime)", "description": "Asthma symptoms during daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma). Lower score (0) is indicating better asthma symptom, while higher score (3) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.", "populationDescription": "Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Change from baseline at week 28", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "67"}, {"groupId": "OG001", "value": "69"}, {"groupId": "OG002", "value": "69"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.32", "spread": "0.56"}, {"groupId": "OG001", "value": "-0.44", "spread": "0.52"}, {"groupId": "OG002", "value": "-0.32", "spread": "0.57"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.998", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Include covariates: treatment group, baseline asthma symptom score, region, visit, and treatment by visit interaction.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.00", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.18", "ciUpperLimit": "0.18"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.177", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Include covariates: treatment group, baseline asthma symptom score, region, visit, and treatment by visit interaction.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.12", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.30", "ciUpperLimit": "0.05"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 28 in Asthma Symptom Scores (Nighttime)", "description": "Asthma symptoms during night time are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma). Lower score (0) is indicating better asthma symptom, while higher score (3) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.", "populationDescription": "Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Change from baseline at week 28", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "67"}, {"groupId": "OG001", "value": "68"}, {"groupId": "OG002", "value": "67"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.27", "spread": "0.51"}, {"groupId": "OG001", "value": "-0.34", "spread": "0.54"}, {"groupId": "OG002", "value": "-0.27", "spread": "0.54"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.973", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Include covariates: treatment group, baseline asthma symptom score, region, visit, and treatment by visit interaction.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.00", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.17", "ciUpperLimit": "0.17"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.480", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Include covariates: treatment group, baseline asthma symptom score, region, visit, and treatment by visit interaction.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.06", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.23", "ciUpperLimit": "0.11"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 28 in Rescue Medication Use", "description": "Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this will be considered as missing. The number of inhalations (puffs) per day will be calculated as follows: Number of night inhaler puffs + 2 x \\[number of night nebulizer times\\] + number of day inhaler puffs + 2 x \\[number of day nebulizer times\\].", "populationDescription": "Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "number of puffs per day", "timeFrame": "Change from baseline at week 28", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "67"}, {"groupId": "OG001", "value": "68"}, {"groupId": "OG002", "value": "67"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.39", "spread": "2.86"}, {"groupId": "OG001", "value": "-2.58", "spread": "4.36"}, {"groupId": "OG002", "value": "-1.07", "spread": "2.86"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.397", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Include covariates: treatment group, baseline total asthma rescue medication use, region, visit, and treatment by visit interaction.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.43", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.44", "ciUpperLimit": "0.57"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.006", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Include covariates: treatment group, baseline total asthma rescue medication use, region, visit, and treatment by visit interaction.", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.41", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.42", "ciUpperLimit": "-0.41"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 28 in Home Lung Function (Morning Peak Expiratory Flow)", "description": "Morning peak expiratory flow change from baseline to week 28. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data.", "populationDescription": "Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liter/min", "timeFrame": "Change from baseline at week 28", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "67"}, {"groupId": "OG001", "value": "68"}, {"groupId": "OG002", "value": "67"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "32.697", "spread": "89.457"}, {"groupId": "OG001", "value": "43.022", "spread": "73.303"}, {"groupId": "OG002", "value": "10.884", "spread": "69.356"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.143", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Include covariates: treatment group, baseline morning PEF, region, visit, and treatment by visit interaction.", "paramType": "Mean Difference (Final Values)", "paramValue": "19.25", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.58", "ciUpperLimit": "45.07"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.023", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Include covariates: treatment group, baseline morning PEF, region, visit, and treatment by visit interaction.", "paramType": "Mean Difference (Final Values)", "paramValue": "30.01", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "4.26", "ciUpperLimit": "55.76"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 28 in Home Lung Function (Evening Peak Expiratory Flow)", "description": "Evening peak expiratory flow change from baseline to week 28. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data", "populationDescription": "Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liter/min", "timeFrame": "Change from baseline at week 28", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "67"}, {"groupId": "OG001", "value": "69"}, {"groupId": "OG002", "value": "66"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "21.885", "spread": "83.136"}, {"groupId": "OG001", "value": "34.157", "spread": "69.287"}, {"groupId": "OG002", "value": "2.933", "spread": "72.302"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.237", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Include covariates: treatment group, baseline evening PEF, region, visit, and treatment by visit interaction.", "paramType": "Mean Difference (Final Values)", "paramValue": "15.19", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-10.08", "ciUpperLimit": "40.46"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.014", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Include covariates: treatment group, baseline evening PEF, region, visit, and treatment by visit interaction.", "paramType": "Mean Difference (Final Values)", "paramValue": "31.52", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "6.32", "ciUpperLimit": "56.71"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 28 in the Proportion of Nights With Awakening Due to Asthma Requiring Rescue Medication", "description": "Baseline is defined as the proportion of nights from the evening of study day -14 to the morning of study day 1.Each timepoint is calculated as bi-weekly proportions based on daily diary data. If more than 50% of data are missing in a 14 day period then this will be considered as missing.Proportion of nights with noctural awakenings is defined as the number of nights with awakenings due to asthma and requiring rescue medication divided by number of nights with data.", "populationDescription": "Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Proportion", "timeFrame": "Change from baseline at week 28", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "67"}, {"groupId": "OG001", "value": "68"}, {"groupId": "OG002", "value": "67"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.158", "spread": "0.283"}, {"groupId": "OG001", "value": "-0.2", "spread": "0.337"}, {"groupId": "OG002", "value": "-0.186", "spread": "0.344"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.742", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Including covariates: treatment group, baseline proportion of nights with noctural awakenings, region, visit, and treatment by visit interaction.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.02", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.08", "ciUpperLimit": "0.11"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.693", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Including covariates: treatment group, baseline proportion of nights with noctural awakenings, region, visit, and treatment by visit interaction.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.02", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.11", "ciUpperLimit": "0.07"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 28 in ACQ-6", "description": "ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of \\<=0.75 indicates well-controlled asthma, scores between 0.75 to \\<=1.5 indicate partly controlled asthma, and \\>1.5 indicates not well controlled asthma.", "populationDescription": "Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Change from baseline at week 28", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "66"}, {"groupId": "OG001", "value": "66"}, {"groupId": "OG002", "value": "67"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.86", "spread": "0.95"}, {"groupId": "OG001", "value": "-1.09", "spread": "1.09"}, {"groupId": "OG002", "value": "-0.68", "spread": "1.10"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.139", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Include covariates: treatment group, baseline ACQ-6 score, region, visit, and treatment by visit interaction.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.24", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.55", "ciUpperLimit": "0.08"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Include covariates: treatment group, baseline ACQ-6 score, region, visit, and treatment by visit interaction.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.55", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.86", "ciUpperLimit": "-0.23"}]}, {"type": "SECONDARY", "title": "ACQ-6 Responders (Improvement) at Week 28", "description": "Improvement is defined as ACQ-6 (End of treatment - baseline) \\<= -0.5. No change is defined as ACQ-6 (End of treatment - baseline) \\>-0.5 and \\<0.5. Deterioration is defined as ACQ-6 (End of treatment - baseline) \\>= 0.5. ACQ-6 score is defined as the average of the first 6 items of the ACQ questionnaire on symptoms, activity limitations and rescue medication.Scores range from 0 (totally controlled) to 6 (severely uncontrolled). Baseline is defined as the last non-missing value prior to randomisation. End of treatment is defined as week 28. Patients with missing or non-evaluable ACQ-6 at week 28 are considered non-responder.", "populationDescription": "Full analysis set", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Week 28", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "72"}, {"groupId": "OG001", "value": "73"}, {"groupId": "OG002", "value": "75"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "41", "spread": "0.95"}, {"groupId": "OG001", "value": "46", "spread": "1.09"}, {"groupId": "OG002", "value": "41", "spread": "1.10"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.658", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Including covariates: treatment group, baseline ACQ-6 score, region, number of exacerbations in the previous year.", "paramType": "Odds Ratio (OR)", "paramValue": "1.165", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.592", "ciUpperLimit": "2.295"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.155", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Including covariates: treatment group, baseline ACQ-6 score, region, number of exacerbations in the previous year.", "paramType": "Odds Ratio (OR)", "paramValue": "1.661", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.826", "ciUpperLimit": "3.340"}]}, {"type": "SECONDARY", "title": "Change From Baseline at Week 28 in AQLQ(S)+12 (Overall)", "description": "AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment). Total or domain score change of \\>=0.5 are considered clinically meaningful.", "populationDescription": "Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "Change from baseline at week 28", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "66"}, {"groupId": "OG001", "value": "67"}, {"groupId": "OG002", "value": "68"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.90", "spread": "0.93"}, {"groupId": "OG001", "value": "1.05", "spread": "1.04"}, {"groupId": "OG002", "value": "0.67", "spread": "1.10"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.151", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Including covariates: treatment group, region, baseline AQLQ(S)+12 score, visit, and treatment by visit interaction.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.23", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.08", "ciUpperLimit": "0.53"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.004", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Including covariates: treatment group, region, baseline AQLQ(S)+12 score, visit, and treatment by visit interaction.", "paramType": "Mean Difference (Final Values)", "paramValue": "0.45", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.14", "ciUpperLimit": "0.76"}]}, {"type": "SECONDARY", "title": "AQLQ(s)+12 Responders (Improvement) at Week 28", "description": "AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. Improvement is defined as AQLQ(S)+12 (End of treatment - baseline)\\>=0.5. No change is defined as AQLQ(S)+12 (End of treatment - baseline) \\>-0.5 and \\<0.5. Deterioration is defined as AQLQ(S)+12 (End of treatment - baseline) \\<= -0.5. Baseline is defined as the last AQLQ(S)+12 score prior to randomisation. End of treatment is defined as week 28. Patients with missing or non-evaluable score at week 28 are considered as non-responder.", "populationDescription": "Full analysis set", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Week 28", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "72"}, {"groupId": "OG001", "value": "73"}, {"groupId": "OG002", "value": "75"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "43", "spread": "0.95"}, {"groupId": "OG001", "value": "44", "spread": "1.09"}, {"groupId": "OG002", "value": "39", "spread": "1.10"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.220", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Including covariates: treatment group, region, baseline AQLQ(S)+12 score, number of exacerbations in the previous year.", "paramType": "Odds Ratio (OR)", "paramValue": "1.538", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.773", "ciUpperLimit": "3.060"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.108", "statisticalMethod": "Regression, Logistic", "statisticalComment": "Including covariates: treatment group, region, baseline AQLQ(S)+12 score, number of exacerbations in the previous year.", "paramType": "Odds Ratio (OR)", "paramValue": "1.783", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.882", "ciUpperLimit": "3.605"}]}, {"type": "SECONDARY", "title": "Extent of Exposure", "description": "Duration of exposure from first dose date to last dose date.", "populationDescription": "Safety analysis set", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Days", "timeFrame": "From first dose to Week 24", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "72"}, {"groupId": "OG001", "value": "73"}, {"groupId": "OG002", "value": "75"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "162.53", "spread": "30.09"}, {"groupId": "OG001", "value": "159.77", "spread": "35.781"}, {"groupId": "OG002", "value": "167.05", "spread": "10.697"}]}]}]}, {"type": "SECONDARY", "title": "Serum Concentration of Benralizumab", "description": "Pre-dose serum concentrations at each visit", "populationDescription": "PK analysis set", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ng/mL", "timeFrame": "Pre-first dose to Week 36", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "72"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"title": "Baseline (n=69, 71)", "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "spread": "NA", "comment": "Value is less than lower limit of quantification"}, {"groupId": "OG001", "value": "NA", "spread": "NA", "comment": "Value is less than lower limit of quantification"}]}]}, {"title": "Week 4 (n=67, 71)", "categories": [{"measurements": [{"groupId": "OG000", "value": "804.37", "spread": "52.77"}, {"groupId": "OG001", "value": "721.42", "spread": "52.30"}]}]}, {"title": "week 8 (n=66, 69)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1152.96", "spread": "53.16"}, {"groupId": "OG001", "value": "1019.65", "spread": "89.51"}]}]}, {"title": "Week 12 (n=68, 67)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1319.14", "spread": "66.05"}, {"groupId": "OG001", "value": "1057.91", "spread": "125.74"}]}]}, {"title": "Week 16 (n=67,67)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1337.98", "spread": "118.90"}, {"groupId": "OG001", "value": "303.54", "spread": "144.53"}]}]}, {"title": "Week 24 (n=65, 66)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1162.62", "spread": "151.35"}, {"groupId": "OG001", "value": "185.17", "spread": "278.32"}]}]}, {"title": "Week 28 (n=65, 65)", "categories": [{"measurements": [{"groupId": "OG000", "value": "1125.96", "spread": "173.79"}, {"groupId": "OG001", "value": "684.57", "spread": "205.67"}]}]}, {"title": "Week 36 (n=2, 4)", "categories": [{"measurements": [{"groupId": "OG000", "value": "11.11", "spread": "2140.87"}, {"groupId": "OG001", "value": "5.92", "spread": "1230.68"}]}]}]}, {"type": "SECONDARY", "title": "Anti-drug Antibody Response", "description": "Number and percentage of patients in different ADA response categories", "populationDescription": "Safety analysis set", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "From baseline to follow-up Week 36", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "72"}, {"groupId": "OG001", "value": "73"}, {"groupId": "OG002", "value": "75"}]}], "classes": [{"title": "Positive at any visit", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "72"}, {"groupId": "OG001", "value": "73"}, {"groupId": "OG002", "value": "75"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "6"}]}]}, {"title": "Baseline and Post-baseline Postive", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "68"}, {"groupId": "OG001", "value": "69"}, {"groupId": "OG002", "value": "75"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "3"}]}]}, {"title": "Only post-baseline positive", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "70"}, {"groupId": "OG002", "value": "75"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "3"}]}]}, {"title": "Only baseline positive", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "69"}, {"groupId": "OG001", "value": "72"}, {"groupId": "OG002", "value": "75"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Persistently positive", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "70"}, {"groupId": "OG002", "value": "75"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "5"}]}]}, {"title": "Transient positive", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "70"}, {"groupId": "OG002", "value": "75"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline in Blood Eosinophil Counts", "description": "Percent change from baseline in blood eosinophil counts at week 28", "populationDescription": "Full analysis set. Number of participants analyzed contains number of participants who had value at Week 28.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent change", "timeFrame": "Change from baseline at Week 28", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "63"}, {"groupId": "OG001", "value": "62"}, {"groupId": "OG002", "value": "66"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-97.4", "spread": "12.93"}, {"groupId": "OG001", "value": "-94.9", "spread": "16.54"}, {"groupId": "OG002", "value": "45.5", "spread": "239.51"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Include covariates: treatment group, baseline eosinophil count, region, visit, treatment by visit", "paramType": "Mean Difference (Final Values)", "paramValue": "-162.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-220.1", "ciUpperLimit": "-104.3", "estimateComment": "Percent change"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Include covariates: treatment group, baseline eosinophil count, region, visit, treatment by visit.", "paramType": "Mean Difference (Final Values)", "paramValue": "-159.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-217.9", "ciUpperLimit": "-100.9", "estimateComment": "Percent change"}]}, {"type": "SECONDARY", "title": "Total Lung Capacity", "description": "Change from baseline in total lung capacity", "populationDescription": "Global Sputum Substudy", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liter", "timeFrame": "From baseline to Week 28", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "26"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"title": "Week 12 (n=17, 23, 17)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.02", "spread": "0.95"}, {"groupId": "OG001", "value": "-0.07", "spread": "0.68"}, {"groupId": "OG002", "value": "-0.30", "spread": "1.08"}]}]}, {"title": "Week 28 (n=14, 18, 15)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.11", "spread": "1.31"}, {"groupId": "OG001", "value": "-0.21", "spread": "0.70"}, {"groupId": "OG002", "value": "-0.47", "spread": "1.47"}]}]}]}, {"type": "SECONDARY", "title": "Residual Volume", "description": "Change from baseline in residual volume", "populationDescription": "Global Sputum Substudy", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liter", "timeFrame": "From baseline to Week 28", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "26"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"title": "Week 12 (n=17, 23, 17)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.02", "spread": "1.00"}, {"groupId": "OG001", "value": "-0.22", "spread": "0.74"}, {"groupId": "OG002", "value": "-0.35", "spread": "1.03"}]}]}, {"title": "Week 28 (n=14, 18, 15)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.07", "spread": "1.34"}, {"groupId": "OG001", "value": "-0.31", "spread": "0.71"}, {"groupId": "OG002", "value": "-0.41", "spread": "1.27"}]}]}]}, {"type": "SECONDARY", "title": "Vital Capacity", "description": "Change from baseline in vital capacity", "populationDescription": "Global Sputum Substudy", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liter", "timeFrame": "From baseline to Week 28", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "26"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"title": "Week 12 (n=17, 24, 18)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.15", "spread": "0.80"}, {"groupId": "OG001", "value": "0.18", "spread": "0.35"}, {"groupId": "OG002", "value": "0.13", "spread": "0.89"}]}]}, {"title": "Week 28 (n=14, 18, 15)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.15", "spread": "0.41"}, {"groupId": "OG001", "value": "0.11", "spread": "0.48"}, {"groupId": "OG002", "value": "-0.08", "spread": "0.41"}]}]}]}, {"type": "SECONDARY", "title": "Functional Residual Capacity", "description": "Change from baseline in functional residual capacity", "populationDescription": "Global Sputum Substudy", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liter", "timeFrame": "From baseline to Week 28", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "26"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"title": "Week 12 (n=17,23, 18)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.05", "spread": "1.06"}, {"groupId": "OG001", "value": "-0.09", "spread": "0.74"}, {"groupId": "OG002", "value": "-0.38", "spread": "0.99"}]}]}, {"title": "Week 28 (n=13,18, 15)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.15", "spread": "1.49"}, {"groupId": "OG001", "value": "-0.26", "spread": "0.74"}, {"groupId": "OG002", "value": "-0.43", "spread": "1.25"}]}]}]}, {"type": "SECONDARY", "title": "Inspiratory Capacity", "description": "Change from baseline in inspiratory capacity", "populationDescription": "Global Sputum Substudy", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liter", "timeFrame": "From baseline to Week 28", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks"}, {"id": "OG001", "title": "Benralizumab 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks"}, {"id": "OG002", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "26"}, {"groupId": "OG002", "value": "23"}]}], "classes": [{"title": "Week 12 (n=17, 23, 17)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.44", "spread": "1.22"}, {"groupId": "OG001", "value": "0.14", "spread": "0.88"}, {"groupId": "OG002", "value": "-0.01", "spread": "0.40"}]}]}, {"title": "Week 28 (n=14, 17, 15)", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.52", "spread": "1.16"}, {"groupId": "OG001", "value": "0.09", "spread": "1.01"}, {"groupId": "OG002", "value": "-0.02", "spread": "0.40"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "timeFrame": "Include events occurred from the start of study treatment to the end of study (up to 36 weeks)", "eventGroups": [{"id": "EG000", "title": "Benra 30 mg q.4 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks", "seriousNumAffected": 7, "seriousNumAtRisk": 72, "otherNumAffected": 34, "otherNumAtRisk": 72}, {"id": "EG001", "title": "Benra 30 mg q.8 Weeks", "description": "Benralizumab administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks", "seriousNumAffected": 7, "seriousNumAtRisk": 73, "otherNumAffected": 34, "otherNumAtRisk": 73}, {"id": "EG002", "title": "Placebo", "description": "Placebo administered subcutaneously", "seriousNumAffected": 14, "seriousNumAtRisk": 75, "otherNumAffected": 49, "otherNumAtRisk": 75}], "seriousEvents": [{"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 75}]}, {"term": "Atrial flutter", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 75}]}, {"term": "Cardiac failure acute", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 75}]}, {"term": "Pericarditis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 75}]}, {"term": "Oesophagitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 75}]}, {"term": "Umbilical hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 75}]}, {"term": "Adverse drug reaction", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 75}]}, {"term": "Gallbladder polyp", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 75}]}, {"term": "Hypersensitivity", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 75}]}, {"term": "Atypical pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 75}]}, {"term": "Chronic sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 75}]}, {"term": "Colonic abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 75}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 75}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 75}]}, {"term": "Pneumonia staphylococcal", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 75}]}, {"term": "Urinary tract infection bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 75}]}, {"term": "Urosepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 75}]}, {"term": "Intervertebral disc protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 75}]}, {"term": "Presyncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 75}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 75}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 5, "numAffected": 4, "numAtRisk": 75}]}, {"term": "Sleep apnoea syndrome", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 75}]}, {"term": "Status asthmaticus", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 75}]}, {"term": "Dermatitis atopic", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 75}]}], "otherEvents": [{"term": "Vertigo", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 1, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 75}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 75}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 5, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 10, "numAffected": 8, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 13, "numAffected": 12, "numAtRisk": 75}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 5, "numAffected": 5, "numAtRisk": 75}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 13, "numAffected": 11, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 14, "numAffected": 12, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 17, "numAffected": 15, "numAtRisk": 75}]}, {"term": "Oral candidiasis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 75}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 7, "numAffected": 6, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 75}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 5, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 5, "numAffected": 4, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 11, "numAffected": 8, "numAtRisk": 75}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 4, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 6, "numAffected": 5, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 7, "numAffected": 5, "numAtRisk": 75}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 5, "numAffected": 4, "numAtRisk": 75}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 5, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 10, "numAffected": 6, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 75}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 6, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 17, "numAffected": 14, "numAtRisk": 75}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 75}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 75}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 72}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 73}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 75}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "\u2265 60 days prior to submission of material for publication/presentation, Institution and PI shall jointly provide AZ with material for review. No publication/presentation may include any of AZ's Confidential Information without AZ's written approval. AZ can request Inst. and PI to withhold material from submission for publication/presentation for an additional 90 days to allow AZ to establish and preserve its proprietary rights in the material being submitted for publication or presentation."}, "pointOfContact": {"title": "Mitchell Goldman, Global Clinical Lead Benralizumab", "organization": "AstraZeneca", "email": "Mitchell.Goldman@astrazeneca.com", "phone": "+1 301 398 0323"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000571386", "term": "Benralizumab"}], "ancestors": [{"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}], "browseLeaves": [{"id": "M287399", "name": "Benralizumab", "asFound": "Aorta", "relevance": "HIGH"}, {"id": "M4854", "name": "Benzocaine", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "T433", "name": "Tannic Acid", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "CNSDep", "name": "Central Nervous System Depressants"}, {"abbrev": "Ot", "name": "Other Dietary Supplements"}]}}, "hasResults": true}